Target | Acquirer | Price |
---|---|---|
Pharmaceuticals | ||
R-Pharm US LLC | Ixempra® | N/A |
AbbVie Inc. | Rights to a Priority Review Voucher | $350 million |
Valeant Pharmaceuticals International | Sprout Pharmaceuticals, Inc. | $1 billion |
Raptor Pharmaceuticals Corp. | Quinsair™ | $68.4 million |
Novartis AG | Remaining rights to ofatumumab | $300 million |